It is important to note that while targeting the IL-6 pathway has shown clinical benefit in acute COVID-19, and this pathway remains aberrant in long COVID, evidence in favor of biological immunomodulatory therapies such as tocilizumab is limited to a case report (77). This evidence concerns the gene IL6 and COVID-19.